Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Gains from Sales and Divestitures: 2024

Historic Gains from Sales and Divestitures for 4D Molecular Therapeutics (FDMT) over the last 1 years, with Dec 2024 value amounting to $52,884.

  • 4D Molecular Therapeutics' Gains from Sales and Divestitures rose 249.59% to $113,785 in Q3 2025 from the same period last year, while for Sep 2025 it was $113,785, marking a year-over-year increase of 249.59%. This contributed to the annual value of $52,884 for FY2024, which is N/A change from last year.
  • As of FY2024, 4D Molecular Therapeutics' Gains from Sales and Divestitures stood at $52,884.
  • Over the past 5 years, 4D Molecular Therapeutics' Gains from Sales and Divestitures peaked at $52,884 during FY2024, and registered a low of $52,884 during FY2024.
  • Its 1-year average for Gains from Sales and Divestitures is $52,884, with a median of $52,884 in 2024.